Prior to joining Blueline in 2014, Joel was an industrial post-doctoral fellow at the Centre for Probe Development and Commercialization. His research at the CPDC involved designing and developing a proprietary linker-payload platform that enables the efficient conversion of antibodies and other targeting vectors into radioimmunoconjugate therapeutics for oncology. The first radioimmunoconjugate developed at the CPDC completed phase I trials in 2014.
In addition to his role at Blueline, Joel serves as a Strategy and Operations Associate at Northern Biologics, an antibody therapeutics start-up financed by Versant and Celgene in 2014.
Joel received a PhD in organic chemistry from the University of Toronto in 2012, where he studied medicinal chemistry and molecular recognition.
Read more Boundless portraits or submit your story.
|
|
home | privacy | events |
